Indeed, in the clinical trial for the C3 inhibitor, APL-2, 18% of patients on monthly injections showed conversion to neovascular AMD, highlighting a critical link between complement inhibition and the risk of increased angiogenic potential (Park et al., 2019). This evidence concerns the gene C3 and age-related macular degeneration.